Holen Sie sich die Stockscreener-App
17.92
0.78%
-0.14
Handel nachbörslich:
18.00
0.08
+0.45%
Dyne Therapeutics Inc Aktie (DYN) Neueste Nachrichten
Dyne Therapeutics (DYN) Shares Key Details For Pivotal. Drugs - Insider Monkey
Assessing Dyne Therapeutics (DYN) Valuation After Phase 3 HARMONIA Launch And New DELIVER Data - simplywall.st
5 Best Day Trading Stocks to Buy Now - Insider Monkey
Dyne Therapeutics launches phase 3 trial for DM1 treatment By Investing.com - Investing.com Nigeria
Dyne Therapeutics (DYN) Q4 Loss Narrows to $0.73/Share vs $0.76 Estimate, Shares Surge 11.8% - AlphaStreet
Dyne Therapeutics (DYN) Climbs 11.8% on Triple-Digit Price Target Upgrade - Finviz
Brian Posner Purchases 3,000 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock - MarketBeat
Nio, Zevra Therapeutics, Vertex Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday - Benzinga
Dyne Therapeutics (DYN) Q4 Loss Narrows to $0.73/Share vs $0.76 Estimate; Shares Surge 19% - AlphaStreet
Jefferies Maintains Buy on Dyne Therapeutics (DYN) March 2026 - Meyka
Dyne Therapeutics (DYN) Receives Analyst Rating Update from Char - GuruFocus
Dyne Therapeutics (NASDAQ:DYN) Trading 11.2% HigherTime to Buy? - MarketBeat
Baird reiterates Dyne Therapeutics stock rating on trial progress By Investing.com - Investing.com Canada
Stifel reiterates Dyne Therapeutics stock rating on DMD data By Investing.com - Investing.com Australia
Dyne Therapeutics: Strong DELIVER Data Strengthens The Bull Case (NASDAQ:DYN) - Seeking Alpha
Stifel reiterates Dyne Therapeutics stock rating on trial design By Investing.com - Investing.com Canada
Jones Trading reiterates Buy on Dyne Therapeutics stock after DMD, DM1 updates - Investing.com
Stifel reiterates Dyne Therapeutics stock rating on DMD data - Investing.com South Africa
Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga
Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1) - Sahm
Rate Hike: Will Dyne Therapeutics Inc benefit from government policy2026 EndofMonth & High Win Rate Trade Alerts - baoquankhu1.vn
Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 - Investing News Network
Dyne Therapeutics (DYN) Begins Phase 3 Trial for Myotonic Dystro - GuruFocus
Dyne Therapeutics (DYN) Reveals Encouraging Results from Zelecim - GuruFocus
Dyne Therapeutics starts Phase 3 HARMONIA trial for z-basivarsen in DM1 - Traders Union
Dyne Therapeutics launches phase 3 trial for DM1 treatment - Investing.com
Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) - Bitget
150-patient Dyne trial focuses on myotonic dystrophy daily function - Stock Titan
Dyne Therapeutics Announces New Positive Cardiopulmonary Results From Deliver Trial Of Z-Rostudirsen In Duchenne Muscular Dystrophy (Dmd) - TradingView
Dyne DMD trial shows better breathing, heart health after 24 months - Stock Titan
DYN SEC FilingsDyne Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
T. Rowe Price (NASDAQ: DYN) lists 26,578,437 shares, a 16.2% stake - Stock Titan
HC Wainwright Predicts Higher Earnings for Dyne Therapeutics - MarketBeat
A Look At Dyne Therapeutics (DYN) Valuation After Q4 2025 Earnings Beat And Ongoing Clinical Progress - Yahoo Finance
FDA curtails Pepgen’s Freedom2 operate in DM1 - bioworld.com
Lifesci Capital Brokers Raise Earnings Estimates for DYN - MarketBeat
Q1 Earnings Estimate for DYN Issued By HC Wainwright - MarketBeat
Rafferty Asset Management LLC Boosts Stake in Dyne Therapeutics, Inc. $DYN - MarketBeat
DYN: Validated platform and pipeline set stage for multiple rare disease launches and growth - TradingView
Dyne Therapeutics, Inc. $DYN Shares Acquired by Vanguard Group Inc. - MarketBeat
A Look At Dyne Therapeutics (DYN) Valuation As Late Stage Pipeline And BLA Plans Gain Momentum - simplywall.st
Morgan Stanley Maintains 'Overweight' on DYN but Lowers Price Ta - GuruFocus
Dyne Therapeutics, Inc. (DYN) Stock Analysis: A Potential 142% Upside in the Biotech Arena - DirectorsTalk Interviews
Chardan Capital Maintains Buy Rating on Dyne Therapeutics (DYN) - GuruFocus
HC Wainwright & Co. Lowers Price Target for Dyne Therapeutics (D - GuruFocus
Analysts Offer Insights on Healthcare Companies: American Well (AMWL) and Dyne Therapeutics (DYN) - The Globe and Mail
Decoding Dyne Therapeutics Inc (DYN): A Strategic SWOT Insight - GuruFocus
Chardan reiterates Dyne Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
DYN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Overweight Maintained for Dyne Therapeutics (DYN) by Morgan Stanley March 2026 - Meyka
Raymond James reiterates Dyne Therapeutics stock rating on FDA pathway By Investing.com - Investing.com Canada
Dyne Therapeutics (NASDAQ:DYN) Shares Down 6.6% After Earnings Miss - MarketBeat
Morgan Stanley cuts Dyne Therapeutics stock price target on model update - Investing.com Canada
Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing - The Motley Fool
Dyne’s Larger 2025 Loss And New Shelf Registration Might Change The Case For Investing In Dyne Therapeutics (DYN) - simplywall.st
Dyne Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Dyne Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Dyne Therapeutics Posts Wider Loss In Q4 - Nasdaq
Dyne Therapeutics (DYN) Beats Q4 EPS Expectations - GuruFocus
Dyne Therapeutics Q4 Net Loss Narrows - marketscreener.com
Dyne Therapeutics Q4 Net Loss Widens - marketscreener.com
Dyne Therapeutics (DYN) Approaches Key Transformation Phase - GuruFocus
Earnings Flash (DYN) Dyne Therapeutics Posts Q4 Net Loss $0.76 a Share, vs. FactSet Est of $0.76 Loss - marketscreener.com
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):